Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2

Stock Information for Nexien BioPharma Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nexien BioPharma Inc

Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents
Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd
Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office
Nexien BioPharma to File Pre-IND Meeting Request with the FDA
Nexien BioPharma Announces Executive and Business Updates
Nexien BioPharma Releases Letter to Shareholders Announcing 2019 Plans, 2018 Activities, and Work to Come From Acquisitions
Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.